Information letter-appeal to healthcare professionals on the safety of use of the medicinal product DEXMEDETOMIDINE B.BRAUN (dexmedetomidine hydrochloride). Increased risk of mortality in intensive care unit patients aged ≤ 65 years

29.09.2026 58 views

Інформаційний лист-звернення до спеціалістів системи охорони здоров’я щодо безпеки застосування лікарського засобу ДЕКСМЕДЕТОМІДИН Б.БРАУНPDF · 168 КБ

Завантажити

Information letter-appeal to healthcare professionals on the safety of use of the medicinal product DEXMEDETOMIDINE B.BRAUN (dexmedetomidine hydrochloride). Increased risk of mortality in intensive care unit patients aged ≤ 65 years

Forum "PHARMEXPERT 2026: pharmaceutical market in the new regulatory reality"

Forum "Clinical and preclinical studies in wartime: organization and development prospects"

Pharmaceutical forum "PHARMEXPERT 2025. eCTD and pricing in Ukraine – a strategic path to integration into the international regulatory space"

PHARMEXPERT 2024. Standards. Innovations. European integration

Information letter-appeal to healthcare professionals on the safety of use of the medicinal product DEXMEDETOMIDINE B.BRAUN (dexmedetomidine hydrochloride). Increased risk of mortality in intensive care unit patients aged ≤ 65 years

Other materials in this section

Forum "PHARMEXPERT 2026: pharmaceutical market in the new regulatory reality"

Forum "Clinical and preclinical studies in wartime: organization and development prospects"

Pharmaceutical forum "PHARMEXPERT 2025. eCTD and pricing in Ukraine – a strategic path to integration into the international regulatory space"

PHARMEXPERT 2024. Standards. Innovations. European integration